InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to 11 new non-executive employees in the aggregate amount of 299,398 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of April 1, 2025, as an inducement material to the employees and the director entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 04/08/2025
|
InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference
- MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 8:00AM Eastern Time / 5:00AM Pacific Time. A live audio webcast and replay of the presentation may be accessed for 90 days on the “News & Events” section of the company's website at: https://www.inspiremd.com/en/events/ About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes.
- 03/26/2025
|
InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript
- NSPR (NASDAQ:NSPR ) Q4 2024 Earnings Conference Call March 12, 2025 8:30 AM ET Company Participants Marvin Slosman - CEO Craig Shore - CFO Shane Gleason - CCO Webb Campbell - IR, Gilmartin Group Conference Call Participants Adam Maeder - Piper Sandler Frank Takkinen - Lake Street Capital Markets Richard Nesbitt - InspireMD Operator Hello and welcome to InspireMD's fourth quarter 2024 earnings conference call. [Operator instructions].
- 03/12/2025
|
InspireMD, Inc. (NSPR) Reports Q4 Loss, Tops Revenue Estimates
- InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago.
- 03/12/2025
|
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results
- MIAMI, March 12, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Engaged with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. ahead of an anticipated first half 2025 approval Announced approval of and enrolled first patients in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures Established headquarters in Miami, Florida, to optimally support the anticipated U.S. commercial launch of CGuard Prime in the first half of 2025, if approved Achieved quarterly revenue and unit records of $1.95M and 3.5K respectively in served markets Marvin Slosman, CEO of InspireMD, commented: “2024 was a year of tremendous progress at InspireMD.
- 03/12/2025
|
InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results
- MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m.
- 02/26/2025
|
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to six new non-executive employees in the aggregate amount of 138,442 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of February 5, 2025, as an inducement material to the employees and the director entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).
- 02/25/2025
|
InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures
- TOLEDO, Ohio and MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to carotid stenosis, and NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, today announced that, pursuant to a previously announced strategic outsourcing partnership, the companies are working together to conduct the CGUARDIANS II pivotal study of InspireMD's CGuard Prime™ 80 cm carotid stent system for use in Transcarotid Artery Revascularization (TCAR) procedures.
- 02/13/2025
|
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- MIAMI, Feb. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to one new non-executive employee in the amount of 18,000 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of January 7, 2025, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 02/04/2025
|
NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study
- InspireMD announces the first patient enrolment in the CGUARDIANS II clinical trial.
- 12/11/2024
|
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
- Study represents a significant step forward in Company's mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutions Study represents a significant step forward in Company's mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutions
- 12/09/2024
|
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors
- MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023.
- 11/25/2024
|
InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript
- InspireMD, Inc. (NASDAQ:NSPR ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Chuck Padala - IR, Life Advisors Marvin Slosman - CEO Craig Shore - CFO Shane Gleason - CCO Conference Call Participants Adam Maeder - Piper Sandler Operator Good day, everyone, and welcome to the InspireMD Third Quarter 2024 Earnings Call. Currently, all participants are in a listen-only mod e.
- 11/12/2024
|
InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates
- InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.15 per share a year ago.
- 11/12/2024
|
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to five new non-executive employees in the aggregate amount of 197,167 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of October 24, 2024, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 11/08/2024
|
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
- MIAMI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the establishment of its global headquarters in Miami, Florida. The new facility will ideally position the Company to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system in the first half of 2025, if approved.
- 10/15/2024
|
InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent
- NSPR gains premarket approval for its CGuard Prime carotid stent system for use in United States for treating carotid artery stenosis.
- 10/10/2024
|
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
- MIAMI, Oct. 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm Carotid Stent System during transcarotid revascularization (TCAR) procedures.
- 10/07/2024
|
NSPR Stock Declines Despite PMA Application Submission for CGuard
- InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.
- 09/17/2024
|
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
- PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were first presented at LINC 2024 in May
- 09/16/2024
|
InspireMD, Inc. (NSPR) Reports Q2 Loss, Misses Revenue Estimates
- InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.
- 08/06/2024
|
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
- - Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial –
- 08/06/2024
|
InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment
- CGuard was the only investigational carotid stent approved by FDA for inclusion in the trials CREST-2 included 23 cases implanted with CGuard TEL AVIV, Israel and MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today congratulated the lead investigators on the completion of enrollment in the CREST-2 (Carotid Revascularization Endarterectomy or Stenting Trial) clinical trials. The CGuard carotid stent, utilizing its proprietary MicroNet™ mesh, was included as a device option for stenting in the CREST-2 trials following FDA approval of InspireMD's Investigational Device Exemption (IDE) supplement application in February 2022.
- 08/05/2024
|
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th
- -Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2024 financial results on Tuesday, August 6th, before the financial markets open.
- 07/30/2024
|
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024
- Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial
- 05/28/2024
|
InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript
- InspireMD Inc. (NASDAQ:NSPR ) Q1 2024 Results Conference Call May 14, 2024 8:30 AM ET Company Participants Chuck Padala - Managing Director Marvin Slosman - President, CEO & Director Craig Shore - CFO, Chief Administrative Officer, Secretary & Treasurer Conference Call Participants Adam Maeder - Piper Sandler Operator Greetings, and welcome to the InspireMD First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
- 05/14/2024
|
InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update
- - Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 -
- 05/14/2024
|
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th
- TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2024 financial results on Tuesday, May 14th, before the financial markets open. Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments.
- 05/07/2024
|
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
- TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024.
- 04/03/2024
|
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
- TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being held May 28-31, in Leipzig, Germany.
- 03/26/2024
|
InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript
- InspireMD Inc. (NASDAQ:NSPR ) Q4 2023 Earnings Conference Call March 6, 2024 8:30 AM ET Company Participants Charles Padala - Investor Relations, LifeSci Advisors Marvin Slosman - President and Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Ben Haynor - Alliance Global Partners Operator Greetings. Welcome to InspireMD Fourth Quarter and Full Year 2023 Earnings Call.
- 03/06/2024
|
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- - Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company's ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, designed to support U.S. approval of CGuard Prime - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D.
- 03/06/2024
|
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
- -Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2023 financial results on Wednesday, March 6th, 2024, before the financial markets open.
- 02/28/2024
|
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
- Development of SwitchGuard™ consistent with Company's mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform Development of SwitchGuard™ consistent with Company's mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform
- 02/12/2024
|
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS
- InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.
- 02/05/2024
|
InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework
- TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it has received CE Mark recertification under the European Union's new Medical Device Regulation (MDR) regulatory framework. MDR replaced the previous MDD framework, which had governed the approval and marketing of medical devices in the EU until May of 2021.
- 01/31/2024
|
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
- Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team
- 01/03/2024
|
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
- Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke
- 12/20/2023
|
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
- TEL AVIV, Israel and MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the company has entered into a strategic agreement with the Jacobs Institute at the State University of New York at Buffalo, and Dr. Adnan Siddiqui, Vice-Chairman and Professor of Neurosurgery, to execute an Early Feasibility Study (EFS) evaluating the CGuard EPS carotid stent to treat severe carotid stenosis or occlusion, in conjunction with thrombectomy, in patients presenting with acute ischemic stroke and tandem lesions. Marvin Slosman, chief executive officer of InspireMD, stated, “This Early Feasibility Study provides the appropriate platform for our investment in this indication to address Carotid lesions in acute stroke settings and reinforces our commitment to the neuro community, as we aim to demonstrate that CGuard EPS is optimally designed with a low metal surface and MicroNet™ mesh covering for superior embolic protection during these acute events.
- 11/27/2023
|
Down -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a Turnaround
- InspireMD, Inc. (NSPR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 11/23/2023
|
InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript
- InspireMD Inc. (NASDAQ:NSPR ) Q3 2023 Results Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Charles Padala - Investor Relations, LifeSci Advisors Marvin Slosman - President, CEO and Director Craig Shore - Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Benjamin Haynor - Alliance Global Partners Operator Good morning. And welcome to the InspireMD Third Quarter of 2023 Earnings Call.
- 11/06/2023
|
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
- - Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from procedure through 30 days at the Vascular InterVentional Advances Annual Meeting (VIVA23) –
- 11/06/2023
|
InspireMD to Participate in Upcoming November Investor Conferences
- TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November:
- 11/02/2023
|
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23
- Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure
- 11/01/2023
|
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th
- -Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2023 financial results on Monday, November 6th, 2023, before the financial markets open.
- 10/30/2023
|
InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th
- -Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2023 financial results on Tuesday, August 8thth, 2023, before the financial markets open.
- 07/25/2023
|
InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast
- - Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host its conference call and webcast to review first quarter 2023 financial and operating results on Tuesday, May 16th, 2023, before the markets open.
- 05/12/2023
|
InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update
- -Conference call and webcast to be held at 8:30 a.m. EDT-
- 03/02/2023
|
InspireMD, Inc. (NSPR) Q3 2022 Earnings Call Transcript
- InspireMD, Inc. (NASDAQ:NSPR ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Chuck Padala - IR, LifeSci Advisors Marvin Slosman - CEO Craig Shore - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Good morning, and welcome to the InspireMD Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.
- 11/08/2022
|
InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update
- -Conference call and webcast to be held at 8:30 a.m. EDT- -Conference call and webcast to be held at 8:30 a.m. EDT-
- 10/25/2022
|
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q2 2022 Results - Earnings Call Transcript
- InspireMD, Inc. (NASDAQ:NSPR ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Chuck Padala - Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Good morning, and welcome to the InspireMD Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.
- 08/09/2022
|
InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update
- - Conference call and webcast to be held at 8:30 a.m. EDT -
- 08/02/2022
|
5 Stocks To Watch For June 6, 2022
- Some of the stocks that may grab investor focus today are: Wall Street expects Science Applications International Corporation (NYSE: SAIC) to report quarterly earnings at $1.77 per share on revenue of $1.93 billion before the opening bell. SAIC shares rose 2.2% to $90.00 in after-hours trading.
- 06/06/2022
|
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q1 2022 Results - Earnings Call Transcript
- InspireMD, Inc. (NASDAQ:NSPR ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Chuck Padala - Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings and welcome to InspireMD First Quarter 2022 Earnings Call. [Operator Instructions] At this time, I'd like to turn the call over to your host, Chuck Padala, LifeSci Advisors.
- 05/10/2022
|
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q4 2021 Results - Earnings Call Transcript
- InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q4 2021 Results - Earnings Call Transcript
- 03/08/2022
|
InspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Business Update
- -Earnings Conference Call to be held Tuesday, March 8, 2022, at 8:30 a.m. ET-
- 02/22/2022
|
InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS)
- - Biennial Scientific Meeting of the IAGS to be held from January 31st – February 3rd 2022 - - Biennial Scientific Meeting of the IAGS to be held from January 31st – February 3rd 2022 -
- 01/27/2022
|
Seeking Income in Challenging Times for Retirement Portfolios
- It's been a shaky start to the year for markets as a hawkish Fed, and the prospect of rising rates has many advisors looking further afield for income opportunities. Strategies that have carried retirement portfolios on an economy of largely solid growth for the last decade or two are now being put to the test [.
- 01/21/2022
|
InspireMD, Inc. (NSPAR) CEO Marvin Slosman on Q3 2021 Results - Earnings Call Transcript
- InspireMD, Inc. (NSPAR) CEO Marvin Slosman on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Best Penny Stocks to Buy Right Now? Here's 3 For Your Watchlist in October
- Are these penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Right Now?
- 10/14/2021
|
NSPR Stock: Why It Increased Today
- The stock price of InspireMD Inc (NASDAQ: NSPR) increased by over 5% today. This is why it happened.
- 10/13/2021
|
InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health
- TEL AVIV, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system has received a positive opinion from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS) regarding reimbursement in France, and the CGuard EPS is being added to the list of reimbursed medical products (LPPR) effective October 25, 2021. This was the final step to full commercial launch of CGuard EPS following CNEDIMTS' positive opinion for reimbursement received by the Company on May 11, 2021 for the treatment of symptomatic and non-symptomatic lesions when surgery is not indicated.
- 10/13/2021
|
2 Net Current Asset Value Stock Picks to Consider
- There are some investors who purchase U.S.-listed stocks that are trading below their liquidation values because they believe they can get a huge return out of these stocks after the market has reappraised the share prices to near or above the liquidation value.
- 09/27/2021
|
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q2 2021 Results - Earnings Call Transcript
- InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q2 2021 Results - Earnings Call Transcript
- 08/10/2021
|
InspireMD Announces Strong Second Quarter 2021 Financial Results
- Revenue rebound, strong procedural recovery
- 08/10/2021
|
InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS
- TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces the initiation of enrollment and successful completion of the first cases of the Company's U.S. registration C-Guardian trial of CGuard EPS.
- 07/23/2021
|
InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
- TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.
- 06/02/2021
|
InspireMD Commences Trading on Nasdaq-CM
- Ticker to remain NSPR Ticker to remain NSPR
- 05/21/2021
|
InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021
- TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021.
- 05/14/2021
|
InspireMD Announces Appointment of Katie Arnold to Board of Directors
- TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced it has appointed seasoned marketing executive Kathryn (Katie) Arnold to its Board of Directors. With more than two decades of strategy and commercialization experience within the medical device industry, Ms. Arnold joins as the company advances global commercialization and enrollment in the U.S. IDE trial of its novel CGuard EPS technology.
- 05/12/2021
|
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q1 2021 Results - Earnings Call Transcript
- InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q1 2021 Results - Earnings Call Transcript
- 05/11/2021
|
InspireMD Announces Stock Exchange Listing Transfer to Nasdaq
- Ticker to remain NSPR Ticker to remain NSPR
- 05/10/2021
|
InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board
- TEL AVIV, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announces the formation of its Scientific Advisory Board with its newly appointed chair, acclaimed interventional cardiologist, Kenneth Rosenfield, M.D.
- 04/29/2021
|
PreMarket Prep Stock Of The Day: InspireMD
- Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.
- 04/27/2021
|
NSPR Stock: What You Should Know About InspireMD Today
- InspireMD has vastly reduced the number of its shares trading ahead of a likely move to a Nasdaq listed. Conversion of NSPR stock warrants and preferred shares will be more difficult now.
- 04/27/2021
|
NSPR Stock: 1-For-15 Reverse Stock Split
- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB) recently announced a 1-for-15 reverse split of its common stock, effective as of yesterday. These are the details.
- 04/27/2021
|
InspireMD Provides Corporate Update for Shareholders
- TEL AVIV, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today provided an update of recent corporate developments.
- 04/19/2021
|
InspireMD Announces 1-for-15 Reverse Stock Split
- TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced a 1-for-15 reverse split of its common stock, effective as of April 26, 2021. Beginning on April 27, 2021, the Company's common stock will trade on the NYSE American on a split adjusted basis.
- 04/14/2021
|
InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results
- Management to host investor conference call today, March 9, at 8:30am ET Management to host investor conference call today, March 9, at 8:30am ET
- 03/09/2021
|
InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update
- Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET
- 03/02/2021
|
InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States
- TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.
- 02/24/2021
|
InspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Registration Trial in the United States
- TEL AVIV, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the appointment of Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee as the principal investigator for its planned FDA registration trial for CGuard EPS.
- 02/09/2021
|
InspireMD Announces Closing of an Upsized $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
- TEL AVIV, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the closing of an upsized underwritten public offering of units for gross proceeds of approximately $20.7 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by InspireMD.
- 02/08/2021
|
InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering
- TEL AVIV, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the pricing of an upsized underwritten public offering of securities for gross proceeds of $18 million (or $20.7 million if the underwriters exercise their option to purchase additional securities) prior to deducting underwriting discounts and estimated offering expenses payable by InspireMD.
- 02/04/2021
|
InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China
- New Chinese Distributor Will Also Invest in At-The-Market Private Placement New Chinese Distributor Will Also Invest in At-The-Market Private Placement
- 02/03/2021
|
InspireMD's CGuard™ Featured in Multiple Presentations, Including a Live Case Demonstration During the Leipzig Interventional Congress January 25-29, 2021
- TEL AVIV, Israel, Jan. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, announced today multiple presentations regarding CGuard EPS, including a live demonstration, during the Leipzig Interventional Congress being held virtually from January 25-29, 2021.
- 01/26/2021
|
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q3 2020 Results - Earnings Call Transcript
- InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
UPDATE - InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)
- TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the appointment of Andrea Tommasoli as senior vice president of global sales and marketing.
- 11/03/2020
|
InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)
- TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the appointment of Andrea Tommasoli as senior vice president of global sales and marketing.
- 11/03/2020
|
InspireMD to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020 and Provide Corporate Update
- Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET
- 11/02/2020
|
Get ready for a good earnings season for big U.S. banks
- The 12 largest U.S. banks are expected to post profits for the third quarter.
- 10/08/2020
|
Mid-Afternoon Market Update: Nasdaq Rises 80 Points; MICT Shares Spike Higher
- Toward the end of trading Tuesday, the Dow traded down 0.13% to 27807.74 while the NASDAQ rose 0.72% to 11,210.10. The S&P also rose, gaining 0.28% to 3,391.38.
The U.S. has...
- 08/18/2020
|
InspireMD Regains Compliance with NYSE AMERICAN Listing Standards
- TEL AVIV, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that as of August 7, 2020, the Company has regained compliance with the NYSE American’s continued listing standards. As previously disclosed, on August 14, 2019, the Company received a Deficiency Letter from the NYSE American stating that InspireMD was not in compliance with certain NYSE American continued listing standards relating to stockholders’ equity. Specifically, InspireMD was not in compliance with Part 10, Section 1003(a)(iii) of the NYSE American Company Guide, due to the fact the Company had reported stockholders’ equity of less than $6 million as of June 30, 2019 and had net losses in its five most recent fiscal years ended December 31, 2018. Following the recently announced funding transaction in which the Company raised net proceeds after offering expenses of approximately $10.7 million, the Company has successfully solved the non-compliance issue.About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable stroke free long-term outcomes.InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.Forward-looking StatementsThis press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) the impact of the COVID-19 pandemic on our manufacturing, sales, business plan and the global economy; (v) intense competition in the medical device industry from much larger, multinational companies, (vi) product liability claims, (vii) product malfunctions, (viii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (ix) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (x) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (xi) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xii) our reliance on single suppliers for certain product components, (xiii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiv) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.Investor Contacts: Craig Shore Chief Financial Officer InspireMD, Inc. 888-776-6804 craigs@inspiremd.com CORE IR investor-relations@inspiremd.com
- 08/10/2020
|
InspireMD's (NSPR) CEO Marvin Slosman on Q2 2020 Results - Earnings Call Transcript
- InspireMD, Inc. (NYSEMKT:NSPR) Q2 2020 Earnings Conference Call August 5, 2020 8:30 AM ET Company Participants Scott Gordon – President of CORE IR, Investor Relations Marvin Slosman – Chief Executive Officer Craig Shore – Chief Financial Officer Conference Call Participants Benjamin Haynor – Alliance Global Partners Presentation Operator Ladies and gentlemen, good day, and welcome to the InspireMD Second Quarter 2020 Financial Results and Corporate Update Conference Call.
- 08/05/2020
|
InspireMD Announces Second Quarter 2020 Financial Results
- In the second quarter the Company was granted approval to market its CGuard™ MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating patients with the CGuard™ MicroNET stent Management to host investor conference call today, August 5, 2020 at 8:30am ETTEL AVIV, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the second quarter ended June 30, 2020.Second Quarter 2020 and recent highlights: * Received approval from the Brazilian registration authority (ANVISA), to market the CGuard™ MicroNet®- covered stent, effectively clearing it for sale and distribution in Brazil. SUPRI Artigos Médicos Hospitalares Ltda. will serve as distribution partner. * Completed an $11.5 million follow-on underwritten public offering, which included $1.5 million from the exercise by the underwriter of its full over-allotment option for the offering. * On June 25, 2020, the U.S. Food and Drug Administration (FDA) granted InspireMD conditional approval of its Investigational Device Exemption (IDE) application to initiate a pivotal study of CGuard™ EPS. We are in the process of addressing the Agency’s remaining requests, specifically related to the stent-embolic protection device (EPD) compatibility performance testing that was previously conducted. * Published 12-month PARDIGM trial results in the journal, EuroIntervention, a prestigious peer-reviewed publication covering the latest advancements in vascular intervention. The paper, titled “Routine MicroNET” details the results of 101 unselected consecutive real-life patients treated with the CGuard™ MicroNET covered stent for carotid stenosis and the 12-month prevention of post-procedural neurologic events. The results indicate that 12 months following carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events. * Announced early results from the investigator-initiated SIBERIA randomized clinical trial of CGuard™ compared to Acculink™, evaluating 30-day silent brain infarcts in 100 patients who qualified for carotid revascularization with high risk for surgery. The results indicated that significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure.“COVID-19 placed significant pressure on the operations of healthcare facilities worldwide, resulting in interruptions in elective procedure volumes, including critical carotid artery treatments. However, we are encouraged by the gradual resumption of these crucial procedures in a growing number of our key markets in Europe and other territories, and we look forward to this expansion taking hold in South America as well. We are also buoyed by the scientific validation we continue to receive in both peer-reviewed publications and opportunities to present at medical conferences where our CGuard MicroNet technology is being recognized as a valued advancement in the carotid stent category,” said Marvin Slosman, InspireMD’s Chief Executive Officer. “Our expansion strategy continues to progress, with our recent Brazilian approval for CGuard™ MicroNet® introducing us to the largest market for medical devices in Latin America and one of the top overall global markets for carotid artery disease. We believe this approval will set the stage for continued expansion into other countries in South America.“We are in the process of addressing the agencies remaining requests, specifically related to the stent-embolic protection device (EPD) compatibility performance testing to gain full FDA approval of our Investigational Device Exemption (IDE) application to initiate a pivotal study of CGuard™ EPS. We have already completed the testing of additional stents according to the FDA’s specifications, and have employed alternative visualization modalities that, we believe, will ultimately allow us to gain full approval. Having an approved IDE is an extremely significant step towards enabling us to initiate a pivotal trial in the United States, clearly one of the world’s most important markets for carotid artery disease and other vascular treatments. We previously indicated that the FDA has concurred with our clinical study design and data requirements to support the market approval of the device. Accordingly, we believe that we are well positioned from a regulatory perspective in terms of our ability to initiate a trial.“In addition, we believe the completion of our $11.5M financing will help ensure we are capable of advancing our commercial expansion and research and development activities as a pillar of our growth objectives. Although the pandemic has put a spotlight on the supply chain infrastructure challenges many in our field are facing, we stand at the ready to fulfill the needs of physicians and their patients for these serious and lifesaving procedures,” Mr. Slosman concluded.Financial Results for the Second Quarter and Six Months ended June 30, 2020For the three months ended June 30, 2020, revenue decreased by $1,041,000, or 76.9%, to $313,000, from $1,354,000 during the three months ended June 30, 2019. This decrease was predominantly driven by a 75.7% decrease in sales volume of CGuard EPS from $1,116,000 during the three months ended June 30, 2019, to $271,000 during the three months ended June 30, 2020. This decrease was mainly due to the fact that procedures with CGuard EPS, which are generally scheduled or non-emergency procedures, were mostly postponed as hospitals shifted resources to patients affected by COVID-19. The decrease was also due to the large shipments of CGuard EPS that we made during the three months ended June 30, 2019 of backlog that accumulated in the three months ended March 31, 2019 that we were unable to ship previously due to our former third-party sterilizer equipment failures. Those large shipments did not recur during the three months ended June 30, 2020. In addition, there was an 82.4% decrease in sales volume of MGuard Prime EPS, from $238,000 during the three months ended June 30, 2019, to $42,000 during the three months ended June 30, 2020, mainly due to similar reasons as mentioned above.The company recorded a gross loss for the quarter ended June 30, 2020 of $120,000, compared to a gross profit of $442,000 for the same period in 2019. This decrease in gross profit resulted primarily from a $448,000 decrease in revenues (as described above), less the related material and labor costs, and a decrease following a receipt of $135,000 compensation received in the quarter ended June 30, 2019 from our former third-party sterilizer for the delays related to the product sterilization interruption during the three months ended March 31, 2019, which did not reoccur in the three months ended June 30, 2020, offset by a $21,000 decrease in miscellaneous expenses. Gross margin (gross profits as a percentage of revenue) decreased to (38.3)% during the three months ended June 30, 2020 from 32.6% during the three months ended June 30, 2019, driven by the reasons mentioned above.Total operating expenses for the quarter ended June 30, 2020 were $2,326,000, a decrease of 11.4% compared to $2,625,000 for the same period in 2019. This decrease was primarily due to a reduction of $382,000 in clinical expenses associated with CGuard EPS, mainly related to the IDE approval process, $235,000 in compensation related to temporary salary reductions due to the immediate impact of COVID-19 on cash flow, and $82,000 of miscellaneous expense reductions offset by an increase of $400,000 due to a settlement agreement with the underwriter of our prior offerings.Financial expenses for the quarter ended June 30, 2020 were $34,000 compared to $23,000 for the same period in 2019. Net loss for the second quarter of 2020 totaled $2,480,000, or $0.20 per basic and diluted share, compared to a net loss of $2,206,000, or $1.59 per basic and diluted share, for the same period in 2019.For the six months ended June 30, 2020, revenue decreased by $422,000, or 23.9%, to $1,347,000, from $1,769,000 during the six months ended June 30, 2019. This decrease was predominantly driven by a 16.8% decrease in sales volume of CGuard EPS from $1,492,000 during the six months ended June 30, 2019, to $1,242,000 during the six months ended June 30, 2020, mainly due to the postponement of procedures with CGuard EPS, which are generally scheduled or non-emergency procedures, as hospitals shifted resources to patients affected by COVID-19. In addition, there was a 62.1% decrease in sales volume of MGuard Prime EPS from $277,000 during the six months ended June 30, 2019, to $105,000 during the six months ended June 30, 2020, mainly due to the impact of COVID-19, as mentioned above.For the six months ended June 30, 2020, gross profit decreased by $194,000, or 52.6%, to $175,000 from $369,000 for the same period in 2019. This decrease in gross profit resulted primarily from a $225,000 decrease in revenues (as mentioned above), less the related material and labor costs and a $61,000 increase in write-offs driven by a non-recurring component supply issue. This decrease was partially offset by a decrease of $69,000 of expenses related to upgrades made to our production facilities during the six months ended June 30, 2019, which did not reoccur during the six months ended in June 30, 2020 and a decrease of $23,000 in miscellaneous expenses during the six months ended June 30, 2020. Gross margin (gross profits as a percentage of revenue) decreased to 13.0% during the six months ended June 30, 2020 from 20.
- 08/05/2020
|
UPDATE: InspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate Update
- Conference Call to be held Wednesday, August 5, 2020 at 8:30am ETTEL AVIV, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal second quarter 2020 financial results on Wednesday, August 5, 2020 at 8:00 AM ET. Management will host a conference call at 8:30AM ET, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question and answer session. Participants are asked to pre-register for the call through the following link: http://dpregister.com/10146840. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the InspireMD call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://services.choruscall.com/links/nspr200805.html, which is also available through the company’s website at https://www.inspiremd.com/en/investors/investor-relations/.A webcast replay of the call will be available approximately one hour after the end of the call through November 4, 2020 at the above links. A telephonic replay of the call will be available through August 19, 2020 and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10146840.About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable stroke free long-term outcomes.InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.Forward-looking StatementsThis press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.Investor Contacts: Craig Shore Chief Financial Officer InspireMD, Inc. 888-776-6804 craigs@inspiremd.com CORE IR investor-relations@inspiremd.com
- 07/29/2020
|
InspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate Update
- Conference Call to be held Thursday, August 5, 2020 at 8:30am ETTEL AVIV, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal second quarter 2020 financial results on Wednesday, August 5, 2020 at 8:00 AM ET. Management will host a conference call at 8:30AM ET, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question and answer session. Participants are asked to pre-register for the call through the following link: http://dpregister.com/10146840. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://services.choruscall.com/links/nspr200805.html, which is also available through the company’s website at https://www.inspiremd.com/en/events/.A webcast replay of the call will be available approximately one hour after the end of the call through November 4, 2020 at the above links. A telephonic replay of the call will be available through August 19, 2020 and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10146840.About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable stroke free long-term outcomes.InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.Forward-looking StatementsThis press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.Investor Contacts: Craig Shore Chief Financial Officer InspireMD, Inc. 888-776-6804 craigs@inspiremd.com CORE IR investor-relations@inspiremd.com
- 07/28/2020
|
InspireMD Gains Registration Clearance of its CGuard™ Embolic Prevention System (EPS) in Brazil
- TEL AVIV, Israel, July 23, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced it has obtained registration from the Brazilian registration authority, Agéncia Nacional de Vigiláncia Sanitária (ANVISA), for its CGuard™ MicroNet®\- covered stent, clearing it for sale and distribution in Brazil.“As the largest market for medical devices in Latin America and one of the top overall global markets for carotid artery disease, the Brazilian registration clearance for CGuard™ is an important accomplishment for our company and represents a significant opportunity to serve an emerging healthcare system. The global carotid artery disease market is expected to reach up to $11.6 billion by 2023, and with an expected 12% CAGR in the overall stent market in Brazil, it is a pillar of our 2020 and 2021 growth strategy,” said Marvin Slosman, InspireMD’s CEO. “We look forward to working with our Brazilian partner, SUPRI Artigos Médicos Hospitalares Ltda, to reach and serve this crucial market with our advanced technology.”Regulatory approval of CGuard™ EPS in Brazil reflects not only the ANVISA'S recognition of CGuard’s differentiating features versus conventional carotid stents, but also the need for safer treatments for carotid artery disease. Brazil ranks as the sixth largest populated country in world and the largest healthcare market in Latin America. With a population over 213 million, Brazil represents an important step toward expanding commercial availability of InspireMD products into new territories.“The Brazilian clearance further supports our goals of broader expansion into South America, particularly into adjacent markets such as Argentina, Mexico and Columbia, and as part of our global expansion strategy, capitalizing on the potential of CGuard™ EPS – and its novel MicroNet® technology – to fundamentally disrupt the current standard of care in carotid artery disease. While the COVID-19 related interruptions have had an impact on elective surgeries worldwide, we expect a resumption in elective procedures as the healthcare system gains a foothold in returning to more normalized operations, as is occurring in our key markets in Europe and other parts of the world. The Brazilian clearance for our CGuard™ EPS represents a milestone in our broader strategy to continue growing our market share in existing markets while expanding in growth markets such as South America, Asia/Pacific, and the U.S. We are also continuing our concerted focus on numerous opportunities for growing our pipeline, leveraging new indications for use of CGuard™ and MicroNet® along with our research into a peri procedural protection device technology as we seek to build upon our strong growth performance in the first quarter of 2020,” Mr. Slosman concluded.Marcos Ramin of SUPRI Artigos Médicos Hospitalares Ltda, added, “At SUPRI, we strive to bring the latest technologies to health care professionals across Brazil, and we are pleased to add CGuard™️ EPS to our portfolio, the most innovative and effective carotid stent available today to prevent embolic stroke of Brazilians.”The CGuard® Embolic Protection System is an advanced platform solution designed to deliver the flexibility of the traditional open cell stent with an advanced protection from peri procedural and post procedural embolic events caused by plaque prolapse through the stent strut that can lead to stroke. CGuard’s unique MicroNet® technology mitigates the prolapse and associated embolization and has shown superior clinical outcomes for patients against alternative carotid stent types, conventional or next generation double layer stents, as well as invasive procedures such as endarterectomy, a major surgical procedure. InspireMD’s CGuard™ has created a new dimension in protected treatment of carotid artery disease with the potential to truly establish a new standard of care for management of carotid artery disease and stroke prevention.About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable stroke free long-term outcomes.InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.Forward-looking StatementsThis press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.Investor Contacts: Craig Shore Chief Financial Officer InspireMD, Inc. 888-776-6804 craigs@inspiremd.com
- 07/23/2020
|
MICT Closes Acquisition of GFH with $15 Million in Committed Funding | Finance Magnates
- MICT has completed the acquisition of a wholly-owned subsidiary of Global Fintech Holdings Ltd. for approximately $25 million in convertible securities.
- 07/02/2020
|
InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR
- TEL AVIV, Israel, June 25, 2020 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by.
- 06/25/2020
|
GlobeX Data CEO Interviewed on Proactiveinvestors.com on Distribution Agreement with Largest Cybersecurity Distributor covering 385 million people | | IT Business Net
- TORONTO, ONTARIO / ACCESSWIRE / June 18, 2020 / GlobeX Data Ltd. (OTCQB:SWISF) (CSE:SWIS) ("GlobeX" or the "Company"), the leader in Swiss hosted cybersecurity and Internet privacy
- 06/18/2020
|
InspireMD (NYSEAMERICAN:NSPR) Downgraded to “Hold” at Zacks Investment Research
- Zacks Investment Research lowered shares of InspireMD (NYSEAMERICAN:NSPR) from a buy rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, “InspireMD Inc. is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The Company’s initial products are […]
- 06/17/2020
|
MICT, Inc. (MICT) Management on Q1 2020 Results - Earnings Call Transcript
- MICT, Inc. (NASDAQ:MICT) Q1 2020 Results Conference Call June 16, 2020 09:00 AM ET Company Participants Darren Mercer - Interim Chief Executive Officer Moran Am
- 06/16/2020
|
GlobeX Data Signs Distribution Agreement with Largest Cybersecurity Distributor in Central, Latin America and Spain Covering Population of 385 Million | | IT Business Net
- TORONTO, ON / ACCESSWIRE / June 16, 2020 / GlobeX Data Ltd. (OTCQB:SWISF) (CSE:SWIS) ("GlobeX" or the "Company"), the leader in Swiss hosted cyber security and Internet privacy sol
- 06/16/2020
|
Barstool Sports’ Dave Portnoy Is Leading an Army of Day Traders
- With sports canceled, Barstool Sports' Dave Portnoy started betting on the stock market instead.
- 06/12/2020
|
Barstool Sports' Dave Portnoy is leading an army of day traders - BNN Bloomberg
- Barstool Sports’ Dave Portnoy had bought just one stock in his life before the quarantine hit. When the country shut down in March, canceling sports and sports betting, the founder of the brash, misogynistic media empire dusted off his old E*Trade account and started day trading.
- 06/12/2020
|
Davey’s miraculous nano-cap trade
- In March, as the coronavirus pandemic forced entire countries into lockdown, Dave Portnoy found himself with two things that often make for a troubling combination: a lot of money and a lot of time. Casino-operator Penn National had just purchased a stake in the media company he founded, Barstool Sports, in a deal that valued the business at $450m and, although he still worked at the company, he needed something else to do while live sport was shuttered. Unlike many Americans, however, he put $3m into it and decided to live blog his day trading with the caveat that “I have zero clue what I’m doing”.
- 06/12/2020
|
InspireMD Announces Publication of 12-Month Results of CGuard™ EPS PARADIGM Trial in EuroIntervention
- Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events TEL.
- 06/10/2020
|
Welcome Hyatt Hotels To Your Portfolio (NYSE:H)
- Hyatt Hotels, with its leading profitability, strong balance sheet, and undervalued stock, presents another excellent buying opportunity for investors willing t
- 06/08/2020
|
InspireMD, Inc. Announces Underwriter Exercise of Over-Allotment Option in Full and Closing of $11.5 Million Follow-On Underwritten Public Offering
- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the closing, on June 5, 2020, of its $11.5 million follow-on underwritten public offering, which included $1.5 million from the exercise, in full, by the underwriter of its over-allotment option for the offering. Pursuant to the offering, InspireMD issued 25,555,500 shares of common stock or common stock equivalents, along with an equivalent number of Series F warrants to purchase common stock, in units, at a price to the public of $0.45 per unit. Each Series F warrant is exercisable for one share of common stock at an exercise price of $0.495 per share.
- 06/08/2020
|
Edited Transcript of NSPR earnings conference call or presentation 12-May-20 12:30pm GMT
- Q1 2020 InspireMD Inc Earnings Call
- 06/04/2020
|
85 Biggest Movers From Yesterday
|
Mid-Afternoon Market Update: Dow Surges 450 Points; Evofem Biosciences Shares Slide
|
58 Stocks Moving In Wednesday's Mid-Day Session
|
Mid-Day Market Update: Gold Falls 2%; FSD Pharma Shares Spike Higher
|
InspireMD shares are trading lower after the company announced a 22.2222M unit offering priced at $0.45 per unit.
|
InspireMD Announces 22.2222M Unit Offering To Be Priced At $0.45/Unit
|
InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering
- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering of 22,222,200 units at a price to the public of $0.45 per unit. InspireMD expects to receive aggregate gross proceeds of approximately $10.0 million from the offering, assuming no exercise of the underwriter’s option to purchase additional securities. Each unit contains one share of common stock (or common stock equivalent) and one Series F warrant to purchase one share of common stock at an exercise price of $0.495 per share.
- 06/03/2020
|
Thinking about buying stock in Zomedica Pharmaceuticals, InspireMD, General Electric, Norwegian ...
|
InspireMD shares are trading lower after the company reported a common stock offering.
|
InspireMD S-1 Shows Registration For $11.5M Common Stock Offering
|
InspireMD shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.
|
InspireMD Announces First Quarter 2020 Financial Results
- First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets Management to host investor.
- 05/12/2020
|
The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
Acceleron Pharma Inc (NASDAQ...
- 05/12/2020
|
Weekly Note, May 11, 2020: Market May Be Entering A Quarantine
- Bad (economic) news is good news. Commodities are a bellwether. Q1 earnings beating expectations. Fiscal stimulus affecting money supply. Business conditions su
- 05/11/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Coronavirus threatens future of eurozone, Brussels warns
- Pandemic risks exacerbating economic and social divisions between countries
- 05/06/2020
|
InspireMD to Report First Quarter 2020 Financial Results and Provide Business Update on Tuesday, May 12
- TEL AVIV, Israel, May 05, 2020 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid.
- 05/05/2020
|
Equinix: In A Single Metric
- Equinix shares have recently reached their 52wk high, in spite of market turbulence. We believe EQIX is benefiting from secular trends, but also unique among da
- 05/01/2020
|
Kraft Heinz Posts Upbeat Q1 Sales Due to Pandemic-Led Demand
- Kraft Heinz delivered better-than-expected results for the first quarter. The company benefited from pantry loading amid the COVID-19 pandemic.
- 04/30/2020
|
Edited Transcript of NSPR earnings conference call or presentation 10-Mar-20 12:30pm GMT
- Q4 2019 InspireMD Inc Earnings Call
- 04/07/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on InspireMD (NSPR), IDEAYA Biosciences (IDYA) and Capricor
- 04/06/2020
|
UPDATE: Traders Suggest InspireMD Spike Higher Related To Slide 8 Of Presentation Showing 'Billion Dollar Market Opportunity' Related To Its MicroNet-Covered Stents Like CGuard Potentially Becoming 'The New Gold Standard'
|
InspireMD, Inc. Just Reported Earnings, And Analysts Cut Their Target Price
- Shareholders in InspireMD, Inc. (NYSEMKT:NSPR) had a terrible week, as shares crashed 33% to US$0.64 in the week since...
- 03/12/2020
|
Analysts Offer Insights on Healthcare Companies: InspireMD (NSPR) and Paratek Pharmaceuticals (PRTK)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on InspireMD (NSPR) and Paratek Pharmaceuticals (PRTK) with
- 03/11/2020
|
H.C. Wainwright Reiterates Buy on InspireMD, Lowers Price Target to $2
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.
- 03/10/2020
|
InspireMD Announces Fourth Quarter and Year-End 2019 Financial Results
- Robust CGuard™ EPS year-over-year revenue growth of 31% Management to host investor conference call today, March 10, at 8:30am ET TEL AVIV, Israel, March 10, 2020 --.
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
InspireMD to Report Fourth Quarter 2019 Financial Results and Provide Business Update on Tuesday, March 10
- TEL AVIV, Israel, March 03, 2020 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by.
- 03/03/2020
|
InspireMD Announces Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2020
- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced that a successful live case featuring CGuard™ EPS was presented at the international LINC conference 2020, which is being held January 28 – 31 in Leipzig, Germany.
- 01/29/2020
|
InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmission at LINC, 28th to the 31st January 2020, in Leipzig, Germany
- TEL AVIV, Israel, Jan. 27, 2020 -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular.
- 01/27/2020
|
DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?
- DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 01/08/2020
|
InspireMD Announces Strong Preliminary Fourth Quarter 2019 Revenue and Reports Inducement Award Under NYSE American Company Guide §711(a)
- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced strong preliminary unaudited revenue for the fourth quarter and reported an inducement grant to the company’s new Chief Executive Officer, Marvin Slosman, who assumed the role effective January 1, 2020. InspireMD anticipates that preliminary unaudited revenue for the fourth quarter ended December 31, 2019, will be within a range of $1,000,000 to $1,025,000, representing estimated growth of 22%-25% over the comparable period in 2018.
- 01/06/2020
|
InspireMD ; Sees Q4 Sales $1M-1.25M
|
Zacks.com featured highlights include: Civeo, InspireMD, Westport Fuel Systems, Genesco and Radware
- Zacks.com featured highlights include: Civeo, InspireMD, Westport Fuel Systems, Genesco and Radware
- 12/19/2019
|
5 Stocks With Rising P/E That Won't Let You Down
- Bet on these top-ranked stocks with rising P/E to realize outsized gains.
- 12/18/2019
|
Nordson: High Growth, But An Overvalued Dividend King - Sure Dividend
- The Dividend Kings are an exclusive list of stocks with 50+ years of dividend increases. This article includes a downloadable list of all Dividend Kings.
- 12/13/2019
|
InspireMD Announces Planned Leadership Transition
- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced that James Barry, Ph.D. is stepping down as President and Chief Executive Officer to pursue other opportunities. The company’s Board of Directors has appointed life sciences industry veteran Marvin Slosman as new Chief Executive Officer, effective January 1, 2020.
- 12/10/2019
|
InspireMD Announces Planned Leadership Transition
|
Cloudera and DocuSign Soar, Zoom Video Falls after Earnings
- Cloudera announced its earnings for the third quarter of fiscal 2020 on Thursday after the market close. The company reported revenues of $198.3 million.
- 12/06/2019
|
Edited Transcript of NSPR earnings conference call or presentation 12-Nov-19 1:30pm GMT
- Q3 2019 InspireMD Inc Earnings Call
- 12/04/2019
|
InspireMD (NSPR) Stock Could Skyrocket Over 370%, Says Analyst
- Medical device company Inspire MD (NSPR), best known for developing innovative MicroNet technology for vascular procedures, has attracted investor attention today following its release of updated registry data at the 2019 VEITH Symposium. As of this writing, Inspire MD shares are soaring nearly 15%.According to the findings, NSPR’s CGuard Embolic Prevention System (EPS) for the prevention of strokes caused by carotid artery disease saw procedural success in 100% of patients in the IRONGUARD 2 study. Not to mention the system isn’t associated with any major periprocedural, 30-day or one-year neurological complications.“The data from long term investigator-initiated multi-center studies presented at VEITH continue to suggest that treatment of carotid artery stenosis with CGuard™ EPS results in lower rates of stroke and restenosis than other treatments presented, including first generation carotid stents, novel double carotid layer stents, and surgical or hybrid techniques,” CEO James Barry, Ph.D. stated.To this end, investors have been left wondering if this positive development represents a turning point for NSPR, which has seen shares tumble year-to-date.H.C. Wainwright analyst Vernon Bernardino believes that this is in fact the case, arguing that the company has already taken several steps in the right direction. The analyst has recently reiterated a Buy rating on NSPR stock along with a $5 price target, as he believes shares could skyrocket 372% over the next twelve months. (To watch Bernardino's track record, click here)Solid Quarterly Performance In its third quarter, NSPR reported that revenue had increased 22% year-over-year to reach $939,000. That was just to kick things off. CGuard EPS saw a record number of orders during the quarter, resulting in sales growth of 41% year-over-year.Bernardino points out that this result was noteworthy as it occurred during a “seasonally soft quarter”, suggesting that awareness of the clinical advantages of CGuard in terms of both conventional carotid stent implantation and carotid endarterectomy (CAE) is increasing. “We believe InspireMD’s strong CGuard sales growth is under-appreciated…InspireMD shares are an attractive value proposition ahead of our projection for continued CGuard sales growth,” he explained.Strong Traction in Education and Outreach ProgramsThe analyst highlights NSPR’s commercial activities like its Centers of Excellence training program as having a positive impact on the awareness of CGuard EPS’s strong clinical data and safety among physicians. Back in 2018, the program was created to train interventional cardiologists using hands-on live patient cases. This program as well as others have contributed to the product’s international expansion.“We believe target introductions in key territories, namely Brazil, which is the fifth-largest market in the world for interventional cardiology procedures, as well as South Korea, Taiwan, Japan and China, which all have attractive pricing for carotid devices, coupled with maturity in the company’s distribution network, represent opportunities for future strong CGuard sales growth,” Bernardino commented.Increased Awareness Through Presentations and Publications Recent presentations and publications have also gone a long way in terms of raising awareness. At the joint Congress of the World Heart Federation and the European Society of Cardiology, the company presented data on a patient level mesh stent meta-analysis from four trials for the first time. The H.C. Wainwright analyst notes that in just one session, NSPR was able to demonstrate the superiority of CGuard EPS versus both first-generation carotid stents and second-generation double layer or mesh-covered carotid devices.The Bottom LineAs Bernardino is the only analyst that has rated the stock in the last three months, NSPR is difficult to gauge. With 1 Buy compared to no Holds or Sells, the consensus is a ‘Moderate Buy.'To find good ideas for biotech stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 11/26/2019
|
InspireMD Reports Updated Positive CGuard™ EPS Data Presented at VEITH 2019
- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today reported on updated registry study data presented at the 2019 VEITH Symposium, which was held November 19-23 in New York City.
- 11/26/2019
|
InspireMD Offers Updated CGuard Data Presented At VEITH 2019
|
Is InspireMD, Inc. (NYSEMKT:NSPR) A Volatile Stock?
- If you own shares in InspireMD, Inc. (NYSEMKT:NSPR) then it's worth thinking about how it contributes to the...
- 11/13/2019
|
InspireMD, Inc. Common Stock Q3 EPS $(1.26) Beats $(1.35) Estimate, Sales $939K Miss $1.4M Estimate
|
45 Biggest Movers From Friday
|
Mid-Morning Market Update: Markets Open Higher; Steelcase Tops Q2 Estimates
|
52 Biggest Movers From Yesterday
|
36 Stocks Moving In Wednesday's Mid-Day Session
|
InspireMD files for equity offering
|
Weighing Opportunity And Risk In A Slow September
|
71 Biggest Movers From Yesterday
|
48 Stocks Moving In Wednesday's Mid-Day Session
|
InspireMD Shares Resume Trade
|
66 Biggest Movers From Yesterday
|
50 Biggest Movers From Yesterday
|
26 Stocks Moving in Monday's Pre-Market Session
|
66 Biggest Movers From Yesterday
|
26 Stocks Moving in Thursday's Pre-Market Session
|
48 Stocks Moving In Monday's Mid-Day Session
|
InspireMD Says Expects To Submit Compliance Plan To NYSE American On Or Before Sep. 6, 2019
|
85 Biggest Movers From Yesterday
|
InspireMD Q2 EPS $(1.59) Beats $(2) Estimate
|
InspireMD (NSPR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
|
64 Biggest Movers From Yesterday
|
42 Stocks Moving In Wednesday's Mid-Day Session
|
58 Biggest Movers From Yesterday
|
InspireMD Q1 EPS $(3.82) Down From $(1.08) YoY, Sales $415K Down From $1.007M YoY
|
Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Fri., May 3, 2019
|
InspireMD shares are trading higher on no apparent news. The stock may be trading higher in sympathy with ARCA Biopharma.
|
42 Biggest Movers From Yesterday
|
28 Stocks Moving In Thursday's Pre-Market Session
|
Empery Asset Management Reports 7.36% Passive Stake In InspireMD
|
Sabby Announces 7.85% Passive Stake In Inspire MD
|
52 Biggest Movers From Yesterday
|
Mid-Afternoon Market Update: Dow Up 135 Points; Recro Pharma Shares Spike Higher
|
InspireMD Reports Offering Of Common Stock, No Size Disclosed
|
InspireMD Reports 1-For-50 Reverse Stock Split, Effective Mar. 29, 2019
|
InspireMD Q4 EPS $(0.05) Up From $(7.38) YoY, Sales $822K Down From $833K YoY
|
The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
|
UPDATE: InspireMD Says 'CGuard™ EPS shows encouraging interim results verses a conventional carotid stent in absence of any adverse clinical events in the CGuard™ arm'
|
InspireMD shares are trading higher after the company announced two successful live clinical clinical case transmissions featuring CGuard EPS.
|
InspireMD Announces Results From Initial Clinical Study Of CGuard Embolic Prevention System (EPS) With SmartFit Technology
|
InspireMD Announced That Its Cguard Carotid Embolic Prevention System Will Be Featured In Two Live Case Transmissions At The Leipzig Interventional Course 2019 To Be Held From January 22-25 At The Trade Fair Leipzig, Hall 2 In Leipzig, Germany
|
InspireMD distributes CGuard system in South Africa
|
InspireMD Reports Received Noncompliance Notice From NYSE American
|
Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018
|
InspireMD up 11% premarket on new data supporting CGuard EPS
|
InspireMD Reports Long-Term Safety, Efficacy Data From Ongoing CGuard EPS Registries At Symposium on Vascular and Endovascular Issues, Techniques, Horizons
|
InspireMD Announces Regulatory And Reimbursement Approval Of CGuard Embolic Prevention System In Australia
|
InspireMD, Inc. Common Stock Q3 EPS $(0.05) Up From $(0.19) YoY, Sales $769K Up From $718K YoY
|
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs
|
UPDATE: InspireMD Highlights 'absence of any device related issues in the first 93 of the 251 patients in the PARADIGM-Extend cohort'
|
InspireMD Announces Regulatory Approval of CGuard Embolic Prevention System in Mexico
|
Stocks Which Set New 52-Week Low Yesterday, September 19th
|
Stocks Which Set New 52-Week Low Yesterday, September 17th
|
InspireMD shares are up 10.6% premarket after the company was issued two new patents covering its MicroNet stent jacket and related drug and related drug eluting Technology.
|
Stocks Which Set New 52-Week Low Yesterday, August 16th
|
Stocks Which Set New 52-Week Low Yesterday, August 15th
|
The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel
|
InspireMD shares up 7.9% after the company reported a year-over-year increase in Q2 EPS and Sales as well as a 94% increase in CGuard EPS revenues.
|
Procter & Gamble earnings Q4 2018 | AlphaStreet
- The Procter & Gamble Company (PG) reported a 3% increase in net sales to $16.5 billion for the fourth quarter of 2018 compared to the same period last year. Organic sales grew 1% driven by a 3% increase in organic shipment volume. Total volume increased 2%.
- 07/31/2018
|
44 Biggest Movers From Friday
|
InspireMD announces pricing of $10M underwritten public offering
|
